ALTRIA GROUP, INC.
For the period ended Jan 28, 2026. Filed Jan 29, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jan 28, 2026 · Filed Jan 29, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Forward-Looking and Cautionary Statements
Forward-Looking and Cautionary Statements
This release contains projections of future results and other forward-looking statements that are subject to a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.
Important factors that could cause actual results to differ materially from those contained in the forward-looking statements included in this release are described in our publicly filed reports, including our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. These factors and risks include the following:
our inability to anticipate and respond to changes in adult nicotine consumer preferences and purchase behavior;
our inability to compete effectively;
the growth of the e-vapor category, including illicit disposable e-vapor products, which contributes to reductions in domestic cigarette consumption levels and shipment volume;
the impact of illicit trade in nicotine products and the sale of products designed to avoid the regulatory framework for nicotine products, each of which contribute to reductions in the consumption levels and shipment volumes of our businesses’ products;
our failure to develop and commercialize innovative products, including nicotine products that may reduce health risks relative to other nicotine products and appeal to adult nicotine consumers;
changes, including in macroeconomic and geopolitical conditions (including inflation and tariffs), that result in shifts in ANC disposable income and purchasing behavior, including choosing lower-priced and discount brands or products, and reductions in shipment volumes;
unfavorable outcomes with respect to litigation proceedings or any governmental investigations, including significant monetary and non-monetary remedies and importation bans;
the risks associated with significant federal, state and local government actions, including FDA regulatory actions and inaction, and various private sector actions;
the risk that regulators, including the FDA, and courts may interpret laws, rules and regulations applicable to our operating companies’ products differently than we do;
increases in nicotine product-related taxes;
our failure to complete or manage successfully strategic relationships or transactions, including acquisitions, dispositions, joint ventures, commercial relationships and investments in third parties, or realize the anticipated benefits of such transactions;
significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of changes in macroeconomic, climate and geopolitical conditions;
our reliance on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers and the risks associated with an extended disruption at a facility or in service by a supplier, distributor or distribution chain service provider;
the risk that we may be required to write down goodwill and intangible assets, including trademarks and other intellectual property, due to impairment;
the risks associated with our Initiative, including risks relating to business continuity, our internal control over financial reporting and audit procedures and our ability to recognize the expected efficiencies;
the risk that we could decide, or be required, to recall products;
the various risks related to health epidemics and pandemics and the measures that international, federal, state and local governments, agencies, law enforcement and health authorities implement to address them;
our inability to attract and retain a highly skilled workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions and other factors;
the risks associated with the various U.S. and foreign laws and regulations to which we are subject due to our international business operations;
the risks concerning a challenge to our tax positions, an increase in the income tax rate or other changes to federal or state tax laws;
the risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters;
disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets;
a downgrade or potential downgrade of our credit ratings;
the impact of heightened focus by investors and other stakeholders on our performance relating to corporate responsibility matters;
the failure of our, or our key service providers’ or key suppliers’, information systems to function as intended, or cyber-attacks or security breaches affecting us or our key service providers or key suppliers;
our failure, or the failure of our key service providers or key suppliers, to comply with laws related to personal data protection, privacy, artificial intelligence and information security;
the risk that the expected benefits of our investment in ABI may not materialize in the expected manner or timeframe or at all; and
the risks associated with our investment in Cronos, including legal, regulatory and reputational risks and the risk that the expected benefits of the transaction may not materialize in the expected manner or timeframe or at all.
You should understand that it is not possible to predict or identify all factors and risks. Consequently, you should not consider the foregoing list to be complete. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law. All subsequent written and oral forward-looking statements attributable to Altria or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.
| Source: Altria Group, Inc. | Altria Client Services | Altria Client Services |
|---|---|---|
| Mac Livingston, Vice President of Investor Relations | Investor Relations | Media Relations |
| Richard.M.Livingston@altria.com | 804-484-8222 | 804-484-8897 |
| www.altria.com/contact-us/media | ||
ALTRIA GROUP, INC.
and Subsidiaries
Consolidated Statements of Earnings
For the Quarters Ended December 31,
(dollars in millions, except per share data)
(Unaudited)
| 2025 | 2024 | % Change | |
|---|---|---|---|
| Net revenues | $5,846 | $5,974 | (2.1)% |
| Cost of sales 1 | 1,448 | 1,502 | |
| Excise taxes on products 1 | 767 | 868 | |
| Gross profit | 3,631 | 3,604 | 0.7% |
| Marketing, administration and research costs | 618 | 601 | |
| Asset impairment and exit costs | 975 | 35 | |
| Impairment of goodwill | 285 | — | |
| Operating companies income | 1,753 | 2,968 | (40.9)% |
| Amortization of intangibles | 20 | 37 | |
| General corporate expenses | 82 | 49 | |
| Operating income | 1,651 | 2,882 | (42.7)% |
| Interest and other debt expense, net | 264 | 255 | |
| Net periodic benefit income, excluding service cost | (14) | (28) | |
| (Income) losses from investments in equity securities 1 | (112) | (122) | |
| Earnings before income taxes | 1,513 | 2,777 | (45.5)% |
| Provision (benefit) for income taxes | 396 | (262) | |
| Net earnings | $1,117 | $3,039 | (63.2)% |
| Per share data: | |||
| Diluted earnings per share | $0.66 | $1.79 | (63.1)% |
| Weighted-average diluted shares outstanding | 1,677 | 1,694 | (1.0)% |
| 1 Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5. | |||
| ALTRIA GROUP, INC. | |||||
|---|---|---|---|---|---|
| and Subsidiaries | |||||
| Selected Financial Data | |||||
| For the Quarters Ended December 31, | |||||
| (dollars in millions) | |||||
| (Unaudited) | |||||
| Net Revenues | |||||
| Smokeable Products · Oral Tobacco Products · E-Vapor Products · All Other · Total | |||||
| 2025 | $5,119 | $706 | $21 | $— | $5,846 |
| 2024 | 5,263 | 692 | 22 | (3) | 5,974 |
| % Change | (2.7)% | 2.0% | (4.5)% | 100.0% | (2.1)% |
| Reconciliation: | |||||
| For the quarter ended December 31, 2024 | $5,263 | $692 | $22 | $(3) | $5,974 |
| Acquisition and disposition-related items - 2025 | — | — | 19 | — | 19 |
| Operations | (144) | 14 | (20) | 3 | (147) |
| For the quarter ended December 31, 2025 | $5,119 | $706 | $21 | $— | $5,846 |
| Operating Companies Income (Loss) | |||||
| Smokeable Products · Oral Tobacco Products · E-Vapor Products · All Other · Total | |||||
| 2025 | $2,643 | $438 | $(1,259) | $(69) | $1,753 |
| 2024 | 2,638 | 453 | (58) | (65) | 2,968 |
| % Change | 0.2% | (3.3)% | (100%+) | (6.2)% | (40.9)% |
| Reconciliation: | |||||
| For the quarter ended December 31, 2024 | $2,638 | $453 | $(58) | $(65) | $2,968 |
| Asset impairment, exit and implementation costs - 2024 | 60 | 8 | — | — | 68 |
| Tobacco and health and certain other litigation items - 2024 | 11 | — | — | — | 11 |
| 71 | 8 | — | — | 79 | |
| NPM Adjustment Items - 2025 | 22 | — | — | — | 22 |
| Acquisition and disposition-related items - 2025 | — | — | 19 | — | 19 |
| Asset impairment, exit and implementation costs - 2025 | (11) | (2) | (1,255) | — | (1,268) |
| Tobacco and health and certain other litigation items - 2025 | (11) | — | — | — | (11) |
| — | (2) | (1,236) | — | (1,238) | |
| Operations | (66) | (21) | 35 | (4) | (56) |
| For the quarter ended December 31, 2025 | $2,643 | $438 | $(1,259) | $(69) | $1,753 |
| ALTRIA GROUP, INC. | |||
|---|---|---|---|
| and Subsidiaries | |||
| Consolidated Statements of Earnings | |||
| For the Years Ended December 31, | |||
| (dollars in millions, except per share data) | |||
| (Unaudited) | |||
| 2025 | 2024 | % Change | |
| Net revenues | $23,279 | $24,018 | (3.1)% |
| Cost of sales 1 | 5,597 | 6,077 | |
| Excise taxes on products 1 | 3,140 | 3,574 | |
| Gross profit | 14,542 | 14,367 | 1.2% |
| Marketing, administration and research costs | 2,120 | 2,122 | |
| Asset impairment and exit costs | 978 | 389 | |
| Impairment of goodwill | 1,158 | — | |
| Operating companies income | 10,286 | 11,856 | (13.2)% |
| Amortization of intangibles | 132 | 139 | |
| General corporate expenses | 255 | 476 | |
| Operating income | 9,899 | 11,241 | (11.9)% |
| Interest and other debt expense, net | 1,079 | 1,037 | |
| Net periodic benefit income, excluding service cost | (59) | (102) | |
| (Income) losses from investments in equity securities 1 | (510) | (652) | |
| Gain on the sale of IQOS System commercialization rights | — | (2,700) | |
| Earnings before income taxes | 9,389 | 13,658 | (31.3)% |
| Provision for income taxes | 2,442 | 2,394 | |
| Net earnings | $6,947 | $11,264 | (38.3)% |
| Per share data2: | |||
| Diluted earnings per share | $4.12 | $6.54 | (37.0)% |
| Weighted-average diluted shares outstanding | 1,683 | 1,718 | (2.0)% |
| 1 Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5. | |||
| 2 Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. | |||
| ALTRIA GROUP, INC. | ||||||
|---|---|---|---|---|---|---|
| and Subsidiaries | ||||||
| Selected Financial Data | ||||||
| For the Years Ended December 31, | ||||||
| (dollars in millions) | ||||||
| (Unaudited) | ||||||
| Net Revenues | ||||||
| Smokeable Products · Oral Tobacco Products · E-Vapor Products · All Other · Total | ||||||
| 2025 | $20,485 | $2,802 | $(13) | $5 | $23,279 | |
| 2024 | 21,204 | 2,776 | 40 | (2) | 24,018 | |
| % Change | (3.4)% | 0.9% | (100%+) | 100%+ | (3.1)% | |
| Reconciliation: | ||||||
| For the year ended December 31, 2024 | $21,204 | $2,776 | $40 | $(2) | $24,018 | |
| Acquisition and disposition-related items - 2025 | — | — | (23) | — | (23) | |
| Operations | (719) | 26 | (30) | 7 | (716) | |
| For the year ended December 31, 2025 | $20,485 | $2,802 | $(13) | $5 | $23,279 | |
| Operating Companies Income (Loss) | ||||||
| Smokeable Products · Oral Tobacco Products · E-Vapor Products · All Other · Total | ||||||
| 2025 | $10,984 | $1,828 | $(2,297) | $(229) | $10,286 | |
| 2024 | 10,821 | 1,449 | (171) | (243) | 11,856 | |
| % Change | 1.5% | 26.2% | (100%+) | (5.8)% | (13.2)% | |
| Reconciliation: | ||||||
| For the year ended December 31, 2024 | $10,821 | $1,449 | $(171) | $(243) | $11,856 | |
| NPM Adjustment Items - 2024 | (29) | — | — | — | (29) | |
| Asset impairment, exit and implementation costs - 2024 | 60 | 362 | — | — | 422 | |
| Tobacco and health and certain other litigation items - 2024 | 70 | — | — | — | 70 | |
| 101 | 362 | — | — | 463 | ||
| NPM Adjustment Items - 2025 | 24 | — | — | — | 24 | |
| Acquisition and disposition-related items - 2025 | — | — | (67) | — | (67) | |
| Asset impairment, exit and implementation costs - 2025 | (49) | (7) | (2,128) | — | (2,184) | |
| Tobacco and health and certain other litigation items - 2025 | (55) | — | — | — | (55) | |
| (80) | (7) | (2,195) | — | (2,282) | ||
| Operations | 142 | 24 | 69 | 14 | 249 | |
| For the year ended December 31, 2025 | $10,984 | $1,828 | $(2,297) | $(229) | $10,286 | |
| Schedule 5 | ||||
|---|---|---|---|---|
| ALTRIA GROUP, INC. | ||||
| and Subsidiaries | ||||
| Supplemental Financial Data | ||||
| (dollars in millions) | ||||
| (Unaudited) | ||||
| For the Quarters Ended December 31, | For the Years Ended December 31, | |||
| 2025 | 2024 | 2025 | 2024 | |
| The segment detail of excise taxes on products sold is as follows: | ||||
| Smokeable products | $743 | $839 | $3,042 | $3,469 |
| Oral tobacco products | 24 | 29 | 98 | 105 |
| $767 | $868 | $3,140 | $3,574 | |
| The segment detail of charges for resolution expenses related to state settlement agreements included in cost of sales is as follows: | ||||
| Smokeable products | $750 | $806 | $3,028 | $3,460 |
| Oral tobacco products | — | — | — | 8 |
| $750 | $806 | $3,028 | $3,468 | |
| The segment detail of FDA user fees included in cost of sales is as follows: | ||||
| Smokeable products | $61 | $59 | $245 | $249 |
| Oral tobacco products | 1 | 1 | 5 | 5 |
| $62 | $60 | $250 | $254 | |
| The detail of (income) losses from investments in equity securities is as follows: | ||||
| ABI | $(102) | $(118) | $(498) | $(673) |
| Cronos | (10) | (4) | (12) | 21 |
| $(112) | $(122) | $(510) | $(652) | |
| ALTRIA GROUP, INC. | ||
|---|---|---|
| and Subsidiaries | ||
| Net Earnings and Diluted Earnings Per Share | ||
| For the Quarters Ended December 31, | ||
| (dollars in millions, except per share data) | ||
| (Unaudited) | ||
| Net Earnings | Diluted EPS | |
| 2025 Net Earnings | $1,117 | $0.66 |
| 2024 Net Earnings | $3,039 | $1.79 |
| % Change | (63.2)% | (63.1)% |
| Reconciliation: | ||
| 2024 Net Earnings | $3,039 | $1.79 |
| 2024 Acquisition and disposition-related items | (13) | — |
| 2024 Asset impairment, exit and implementation costs | 51 | 0.03 |
| 2024 Tobacco and health and certain other litigation items | 8 | — |
| 2024 Amortization of intangibles | 30 | 0.01 |
| 2024 ABI-related special items | 32 | 0.02 |
| 2024 Cronos-related special items | (5) | — |
| 2024 Income tax items | (928) | (0.55) |
| Subtotal 2024 special items 1 | (825) | (0.49) |
| 2025 NPM Adjustment Items | 13 | 0.01 |
| 2025 Acquisition and disposition-related items | 14 | 0.01 |
| 2025 Asset impairment, exit and implementation costs | (1,015) | (0.61) |
| 2025 Tobacco and health and certain other litigation items | (7) | — |
| 2025 Amortization of intangibles | (18) | (0.01) |
| 2025 ABI-related special items | (47) | (0.03) |
| 2025 Cronos-related special items | 7 | — |
| 2025 Income tax items | (12) | (0.01) |
| Subtotal 2025 special items | (1,065) | (0.64) |
| Fewer shares outstanding | — | 0.01 |
| Change in tax rate | 38 | 0.02 |
| Operations | (70) | (0.03) |
| 2025 Net Earnings | $1,117 | $0.66 |
| 1 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures. | ||
| ALTRIA GROUP, INC. | ||||||
|---|---|---|---|---|---|---|
| and Subsidiaries | ||||||
| Reconciliation of GAAP and non-GAAP Measures | ||||||
| For the Quarters Ended December 31, | ||||||
| (dollars in millions, except per share data) | ||||||
| (Unaudited) | ||||||
| Earnings before Income Taxes · Provision (benefit) for Income Taxes · Net Earnings · Diluted EPS | ||||||
| 2025 Reported | $1,513 | $396 | $1,117 | $0.66 | ||
| NPM Adjustment Items | (18) | (5) | (13) | (0.01) | ||
| Acquisition and disposition-related items | (20) | (6) | (14) | (0.01) | ||
| Asset impairment, exit and implementation costs | 1,268 | 253 | 1,015 | 0.61 | ||
| Tobacco and health and certain other litigation items | 10 | 3 | 7 | — | ||
| Amortization of intangibles | 20 | 2 | 18 | 0.01 | ||
| ABI-related special items | 59 | 12 | 47 | 0.03 | ||
| Cronos-related special items | (7) | — | (7) | — | ||
| Income tax items | — | (12) | 12 | 0.01 | ||
| 2025 Adjusted for Special Items | $2,825 | $643 | $2,182 | $1.30 | ||
| 2024 Reported | $2,777 | $(262) | $3,039 | $1.79 | ||
| Acquisition and disposition-related items | (14) | (1) | (13) | — | ||
| Asset impairment, exit and implementation costs | 68 | 17 | 51 | 0.03 | ||
| Tobacco and health and certain other litigation items | 11 | 3 | 8 | — | ||
| Amortization of intangibles | 37 | 7 | 30 | 0.01 | ||
| ABI-related special items | 41 | 9 | 32 | 0.02 | ||
| Cronos-related special items | (4) | 1 | (5) | — | ||
| Income tax items | — | 928 | (928) | (0.55) | ||
| 2024 Adjusted for Special Items 1 | $2,916 | $702 | $2,214 | $1.30 | ||
| 2025 Reported Net Earnings and Reported Diluted EPS | $1,117 | $0.66 | ||||
| 2024 Reported Net Earnings and Reported Diluted EPS | $3,039 | $1.79 | ||||
| % Change | (63.2)% | (63.1)% | ||||
| 2025 Adjusted Net Earnings and Adjusted Diluted EPS | $2,182 | $1.30 | ||||
| 2024 Adjusted Net Earnings and Adjusted Diluted EPS | $2,214 | $1.30 | ||||
| % Change | (1.4)% | —% | ||||
| 1 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures. | ||||||
| ALTRIA GROUP, INC. | ||
|---|---|---|
| and Subsidiaries | ||
| Net Earnings and Diluted Earnings Per Share | ||
| For the Years Ended December 31, | ||
| (dollars in millions, except per share data) | ||
| (Unaudited) | ||
| Net Earnings | Diluted EPS1 | |
| 2025 Net Earnings | $6,947 | $4.12 |
| 2024 Net Earnings | 11,264 | $6.54 |
| % Change | (38.3)% | (37.0)% |
| Reconciliation: | ||
| 2024 Net Earnings | $11,264 | $6.54 |
| 2024 NPM Adjustment Items | (20) | (0.01) |
| 2024 Acquisition and disposition-related items | (1,862) | (1.08) |
| 2024 Asset impairment, exit and implementation costs | 315 | 0.18 |
| 2024 Tobacco and health and certain other litigation items | 76 | 0.04 |
| 2024 Amortization of intangibles | 115 | 0.07 |
| 2024 ABI-related special items | 2 | — |
| 2024 Cronos-related special items | 15 | 0.01 |
| 2024 Income tax items | (969) | (0.56) |
| Subtotal 2024 special items2 | (2,328) | (1.35) |
| 2025 NPM Adjustment Items | 15 | 0.01 |
| 2025 Acquisition and disposition-related items | (66) | (0.04) |
| 2025 Asset impairment, exit and implementation costs | (1,921) | (1.14) |
| 2025 Tobacco and health and certain other litigation items | (44) | (0.03) |
| 2025 Amortization of intangibles | (110) | (0.06) |
| 2025 ABI-related special items | (75) | (0.04) |
| 2025 Cronos-related special items | 5 | — |
| 2025 Income tax items | (5) | — |
| Subtotal 2025 special items | (2,201) | (1.30) |
| Fewer shares outstanding | — | 0.11 |
| Change in tax rate | 119 | 0.07 |
| Operations | 93 | 0.05 |
| 2025 Net Earnings | $6,947 | $4.12 |
| 1 Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. | ||
| 2 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures. | ||
each period.
| ALTRIA GROUP, INC. | |||||
|---|---|---|---|---|---|
| and Subsidiaries | |||||
| Reconciliation of GAAP and non-GAAP Measures | |||||
| For the Years Ended December 31, | |||||
| (dollars in millions, except per share data) | |||||
| (Unaudited) | |||||
| Earnings before Income Taxes · Provision for Income Taxes · Net Earnings · Diluted EPS1 | |||||
| 2025 Reported | $9,389 | $2,442 | $6,947 | $4.12 | |
| NPM Adjustment Items | (20) | (5) | (15) | (0.01) | |
| Acquisition and disposition-related items | 76 | 10 | 66 | 0.04 | |
| Asset impairment, exit and implementation costs | 2,184 | 263 | 1,921 | 1.14 | |
| Tobacco and health and certain other litigation items | 58 | 14 | 44 | 0.03 | |
| Amortization of intangibles | 132 | 22 | 110 | 0.06 | |
| ABI-related special items | 95 | 20 | 75 | 0.04 | |
| Cronos-related special items | (5) | — | (5) | — | |
| Income tax items | — | (5) | 5 | — | |
| 2025 Adjusted for Special Items | $11,909 | $2,761 | $9,148 | $5.42 | |
| 2024 Reported | 13,658 | 2,394 | 11,264 | 6.54 | |
| NPM Adjustment Items | (27) | (7) | (20) | (0.01) | |
| Acquisition and disposition-related items | (2,527) | (665) | (1,862) | (1.08) | |
| Asset impairment, exit and implementation costs | 422 | 107 | 315 | 0.18 | |
| Tobacco and health and certain other litigation items | 101 | 25 | 76 | 0.04 | |
| Amortization of intangibles | 139 | 24 | 115 | 0.07 | |
| ABI-related special items | 2 | — | 2 | — | |
| Cronos-related special items | 18 | 3 | 15 | 0.01 | |
| Income tax items | — | 969 | (969) | (0.56) | |
| 2024 Adjusted for Special Items2 | $11,786 | $2,850 | $8,936 | $5.19 | |
| 2025 Reported Net Earnings and Reported Diluted EPS | $6,947 | $4.12 | |||
| 2024 Reported Net Earnings and Reported Diluted EPS | $11,264 | $6.54 | |||
| % Change | (38.3)% | (37.0)% | |||
| 2025 Adjusted Net Earnings and Adjusted Diluted EPS | $9,148 | $5.42 | |||
| 2024 Adjusted Net Earnings and Adjusted Diluted EPS | $8,936 | $5.19 | |||
| % Change | 2.4% | 4.4% | |||
| 1 Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. | |||||
| 2 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures. | |||||
| ALTRIA GROUP, INC. | ||
|---|---|---|
| and Subsidiaries | ||
| Condensed Consolidated Balance Sheets | ||
| (dollars in millions) | ||
| (Unaudited) | ||
| December 31, 2025 | December 31, 2024 | |
| Assets | ||
| Cash and cash equivalents | $4,474 | $3,127 |
| Inventories | 1,070 | 1,080 |
| Other current assets | 388 | 306 |
| Property, plant and equipment, net | 1,710 | 1,617 |
| Goodwill and other intangible assets, net | 17,663 | 19,918 |
| Investments in equity securities | 8,617 | 8,195 |
| Other long-term assets | 1,095 | 934 |
| Total assets | $35,017 | $35,177 |
| Liabilities and Stockholders’ Equity (Deficit) | ||
| Current portion of long-term debt | $1,569 | $1,527 |
| Accrued settlement charges | 2,178 | 2,354 |
| Other current liabilities | 5,407 | 4,900 |
| Long-term debt | 24,140 | 23,399 |
| Deferred income taxes | 3,370 | 3,749 |
| Accrued pension costs | 122 | 136 |
| Accrued postretirement health care costs | 939 | 935 |
| Other long-term liabilities | 744 | 365 |
| Total liabilities | 38,469 | 37,365 |
| Total stockholders’ equity (deficit) attributable to Altria | (3,502) | (2,238) |
| Noncontrolling interest | 50 | 50 |
| Total liabilities and stockholders’ equity (deficit) | $35,017 | $35,177 |
| Total debt | $25,709 | $24,926 |
| ALTRIA GROUP, INC. | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| and Subsidiaries | |||||||||
| Supplemental Financial Data for Special Items | |||||||||
| For the Quarters Ended December 31, | |||||||||
| (dollars in millions) | |||||||||
| (Unaudited) | |||||||||
| Net Revenues | Cost ofSales | Marketing, administration and research costs | Impairment of goodwill | Amortization of intangibles | Asset impairment and exit costs | Generalcorporateexpenses | Interest and other debt (income) expense, net | (Income) losses from investments in equity securities | |
| 2025 Special Items - (Income) Expense | |||||||||
| NPM Adjustment Items | $— | $(22) | $— | $— | $— | $— | $— | $4 | $— |
| Acquisition and disposition-related items | (19) | — | — | — | — | — | (1) | — | — |
| Asset impairment, exit and implementation costs | — | — | 8 | 285 | — | 975 | — | — | — |
| Tobacco and health and certain other litigation items | — | — | 11 | — | — | — | — | (1) | — |
| Amortization of intangibles | — | — | — | — | 20 | — | — | — | — |
| ABI-related special items | — | — | — | — | — | — | — | — | 59 |
| Cronos-related special items | — | — | — | — | — | — | — | — | (7) |
| Acquisition and disposition-related items | — | — | — | — | — | — | (14) | — | — |
| Asset impairment, exit and implementation costs | — | — | 33 | — | — | 35 | — | — | — |
| Tobacco and health and certain other litigation items | — | — | 11 | — | — | — | — | — | — |
| Amortization of intangibles | — | — | — | — | 37 | — | — | — | — |
| ABI-related special items | — | — | — | — | — | — | — | — | 41 |
| Cronos-related special items | — | — | — | — | — | — | — | — | (4) |
Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in Altria’s consolidated statements of earnings. This schedule is not intended to provide, or reconcile, non-GAAP financial measures.
1 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.
| ALTRIA GROUP, INC. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| and Subsidiaries | ||||||||||
| Supplemental Financial Data for Special Items | ||||||||||
| For the Years Ended December 31, | ||||||||||
| (dollars in millions) | ||||||||||
| (Unaudited) | ||||||||||
| Net Revenues | Cost ofSales | Marketing, administration and research costs | Amortization of intangibles | Asset impairment and exit costs | Impairment of goodwill | General corporate expenses | Interest and other debt (income) expense, net | (Income) losses from investments in equity securities | Gain on the sale of IQOS System commerciali-zation rights | |
| 2025 Special Items - (Income) Expense | ||||||||||
| NPM Adjustment Items | $— | $(24) | $— | $— | $— | $— | $— | $4 | $— | $— |
| Acquisition and disposition-related items | 23 | 44 | — | — | — | — | 9 | — | — | — |
| Asset impairment, exit and implementation costs | — | — | 48 | — | 978 | 1,158 | — | — | — | — |
| Tobacco and health and certain other litigation items | — | — | 55 | — | — | — | — | 3 | — | — |
| Amortization of intangibles | — | — | — | 132 | — | — | — | — | — | — |
| ABI-related special items | — | — | — | — | — | — | (1) | — | 96 | — |
| Cronos-related special items | — | — | — | — | — | — | — | — | (5) | — |
| NPM Adjustment Items | $— | $(29) | $— | $— | $— | $— | $— | $2 | $— | $— |
| Acquisition and disposition-related items | — | — | — | — | — | — | 173 | — | — | (2,700) |
| Asset impairment, exit and implementation costs | — | — | 33 | — | 389 | — | — | — | — | — |
| Tobacco and health and certain other litigation items | — | — | 70 | — | — | — | 30 | 1 | — | — |
| Amortization of intangibles | — | — | — | 139 | — | — | — | — | — | — |
| ABI-related special items | — | — | — | — | — | — | 59 | 3 | (60) | — |
| Cronos-related special items | — | — | — | — | — | — | — | — | 18 | — |
Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in Altria’s consolidated statements of earnings. This schedule is not intended to provide, or reconcile, non-GAAP financial measures.
1 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.
| ALTRIA GROUP, INC. | ||
|---|---|---|
| and Subsidiaries | ||
| Supplemental Retail Share Data | ||
| (Unaudited) | ||
| Retail share results for oral tobacco products are based on data from Circana, a tracking service that uses a sample of stores to project market share and depict share trends. In the fourth quarter of 2025, Circana refreshed its retail scan data to account for a retailer data revision that impacted on! and total oral tobacco products retail share data for the second and third quarters of 2025. It is the standard practice of retail services to periodically refresh their retail scan services, which could restate retail share results that were previously released in these services. This update impacted previously reported retail share performance for on! and total oral tobacco products. Restated share results are summarized below. | ||
| Retail Share (percent) | ||
| For the Three Months Ended | ||
| 9/30/2025 | 6/30/2025 | |
| on! | 8.3 | 8.4 |
| Total oral tobacco products | 30.9% | 32.9% |
| Retail Share (percent) | ||
| For the Nine Months Ended | For the Six Months Ended | |
| 9/30/2025 | 6/30/2025 | |
| on! | 8.4 | 8.5 |
| Total oral tobacco products | 32.8% | 33.8% |
| Schedule 14 | |
|---|---|
| ALTRIA GROUP, INC. | |
| and Subsidiaries | |
| Calculation of Total Debt to Consolidated EBITDA and Net Debt to Consolidated EBITDA Ratios | |
| For the Twelve Months Ended December 31, 2025 1 | |
| (dollars in millions) | |
| (Unaudited) | |
| Total | |
| Consolidated Net Earnings | $6,947 |
| Interest and other debt expense, net | 1,079 |
| Provision for income taxes | 2,442 |
| Depreciation and amortization | 266 |
| EBITDA 2 | 10,734 |
| (Income) loss from investments in equity securities and noncontrolling interest, net | (510) |
| Dividends from less than 50% owned affiliates | 208 |
| Fair value adjustment for NJOY Transaction contingent payments | 25 |
| Impairment of goodwill | 1,158 |
| Asset impairment and exit costs | 978 |
| Consolidated EBITDA 3 | $12,593 |
| Current portion of long-term debt | $1,569 |
| Long-term debt | 24,140 |
| Total Debt 4 | 25,709 |
| Cash and cash equivalents 5 | 4,474 |
| Net Debt 6 | $21,235 |
| Ratios: | |
| Total Debt / Consolidated Net Earnings | 3.7 |
| Total Debt / Consolidated EBITDA | 2.0 |
| Net Debt / Consolidated EBITDA | 1.7 |
| 1 Calculated as of the end of the applicable quarter on a rolling four quarters basis. | |
| 2 Reflects earnings before interest, taxes, depreciation and amortization (“EBITDA”). | |
| 3 Reflects the term “Consolidated EBITDA” as defined in Altria’s revolving credit agreement. | |
| 4 Reflects total debt as presented on Altria’s Consolidated Balance Sheet at December 31, 2025. See Schedule 10. | |
| 5 Reflects cash and cash equivalents as presented on Altria’s Consolidated Balance Sheet at December 31, 2025. See Schedule 10. | |
| 6 Reflects total debt, less cash and cash equivalents at December 31, 2025. | |
| Schedule 15 | |||||
|---|---|---|---|---|---|
| ALTRIA GROUP, INC. | |||||
| and Subsidiaries | |||||
| Reconciliation of Reported OCI to Adjusted OCI | |||||
| For the Year Ended December 31, 2025 | |||||
| (dollars in millions) | |||||
| (Unaudited) | |||||
| Smokeable Products | Oral Tobacco Products | E-Vapor Products | All Other | Total | |
| Net revenues | $20,485 | $2,802 | $(13) | $5 | $23,279 |
| Excise taxes | (3,042) | (98) | — | — | (3,140) |
| Revenues net of excise taxes | $17,443 | $2,704 | $(13) | $5 | $20,139 |
| Reported operating companies income (OCI) | $10,984 | $1,828 | $(2,297) | $(229) | $10,286 |
| NPM Adjustment Items | (24) | — | — | — | (24) |
| Acquisition and disposition-related items | — | — | 67 | — | 67 |
| Asset impairment, exit and implementation costs | 49 | 7 | 2,128 | — | 2,184 |
| Tobacco and health and certain other litigation items | 55 | — | — | — | 55 |
| Adjusted OCI | $11,064 | $1,835 | $(102) | $(229) | $12,568 |
| Reported OCI margins 1 | 63.0% | 67.6% | (100%+) | (100%+) | 51.1% |
| Adjusted OCI margins 1 | 63.4% | 67.9% | (100%+) | (100%+) | 62.4% |
| Schedule 16 | |||
|---|---|---|---|
| ALTRIA GROUP, INC. | |||
| and Subsidiaries | |||
| Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS | |||
| For the Years Ended December 31, 2025 and 2022 | |||
| (Unaudited) | |||
| For the Years Ended December 31, · Compounded Annual Growth Rate | |||
| 2025 · 2022 | |||
| Reported diluted EPS | $4.12 | $3.19 | 8.9% |
| NPM Adjustment Items | (0.01) | (0.03) | |
| Acquisition and disposition-related items | 0.04 | — | |
| Asset impairment, exit and implementation costs | 1.14 | — | |
| Tobacco and health and certain other litigation items | 0.03 | 0.05 | |
| Amortization of intangibles 1 | 0.06 | 0.03 | |
| JUUL changes in fair value | — | 0.81 | |
| ABI-related special items | 0.04 | 1.12 | |
| Cronos-related special items | — | 0.10 | |
| Income tax items | — | (0.40) | |
| Adjusted diluted EPS | $5.42 | $4.87 | 3.6% |
1 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.